Clinical Trial News and Research

RSS

Cordis announces launch of ExoSeal Vascular Closure Device

Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, announced the launch of the ExoSeal(TM) Vascular Closure Device. ExoSeal(TM) incorporates a number of new advances in technology and simplicity of design to provide precise and secure extravascular arterial closure. Cordis Corporation received CE-Marking approval for ExoSeal(TM) Vascular Closure Device in May 2010.

27 May 2010

UCI scientists create eight-layer, early-stage retina from human embryonic stem cells

UC Irvine scientists have created an eight-layer, early-stage retina from human embryonic stem cells, the first three-dimensional tissue structure to be made from stem cells.

27 May 2010

Modified measles virus may hold potential for treatment of medulloblastoma

The use of modified measles virus may represent a new treatment for a childhood brain tumor known as medulloblastoma, according to a new study appearing in Neuro-Oncology.

27 May 2010

Nottingham scientists given green light to test new vaccine for malignant melanoma

Nottingham scientists have been given the green light to test a vaccine which they hope could reverse, and even cure malignant melanoma, the most deadly type of skin cancer.

27 May 2010

PBI awarded contract to provide essential laboratory data for Phase I cardiovascular trial

Pacific Biomarkers, Inc. has been awarded a contract by a leading multinational pharmaceutical company to provide essential laboratory data for an adaptive Phase I cardiovascular trial. This study is part of a major drug-development program to evaluate an innovative new treatment to reduce recurrent cardiovascular events associated with acute coronary syndrome.

27 May 2010

Cardiovascular Systems initiates enrollment in ORBIT II IDE clinical trial of Diamondback 360 System

Cardiovascular Systems, Inc., announces the first patient enrollment in its ORBIT II Investigational Device Exemption (IDE) clinical trial to evaluate the safety and effectiveness of its Diamondback 360® System in treating coronary arteries. The patient was treated by Dr. P.K. Khanna, an interventional cardiologist with Eisenhower Medical Center in Palm Springs, Calif. Dr. Khanna also treated patients in the 2008 ORBIT I coronary study of 50 patients in India.

26 May 2010

CTRC starts enrolment in Phase 2 combination trial of REOLYSIN and gemcitabine for advanced pancreatic cancer

Oncolytics Biotech Inc. announced today that the Cancer Therapy & Research Center at the University of Texas Health Science Center in San Antonio (CTRC) has started patient enrolment in a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with gemcitabine (Gemzar(R)) in patients with advanced pancreatic cancer. The Principal Investigator is Dr. Monica Mita of the CTRC.

26 May 2010

New clinical data for CoreValve transcatheter aortic valve replacement system presented at EuroPCR

New clinical data presented today at EuroPCR demonstrate positive long-term performance and durability for the CoreValve transcatheter aortic valve replacement system from Medtronic, Inc. Two-year results from the pivotal 18-French CoreValve multicenter prospective study provide important additional evidence supporting wider use of the world's market-leading transcatheter aortic valve.

26 May 2010

Medtronic’s Resolute zotarolimus-eluting stent as effective as Xience V everolimus-eluting stent: Study

The highly anticipated first results of the RESOLUTE All Comers study were presented today during the late-breaking clinical trial session of the 2010 EuroPCR meeting. In this novel 2,292-patient randomized trial, the Resolute zotarolimus-eluting stent from Medtronic, Inc. was found to be as safe and effective as the Xience® V everolimus-eluting stent from Abbott Laboratories.

26 May 2010

6-month results of NovoStent's SAMBA trial for atherosclerotic disease in SFA and popliteal arteries

NovoStent Corporation, a privately held medical device company, today announced the 6-month follow-up results of the company's European clinical trial evaluating the use of its SAMBA Stent and Delivery System in the treatment of superficial femoral and popliteal artery disease. The SAMBA Stent was designed to treat the highly varied presentation of atherosclerotic disease in the superficial femoral (SFA) and popliteal arteries by providing a unique combination of increased vessel coverage, strength and flexibility.

26 May 2010

Boston Scientific initiates study to compare PROMUS Element Stent to XIENCE PRIME Stent System

Boston Scientific Corporation today announced the initiation of the PLATINUM PLUS clinical trial, an investigator-sponsored research (ISR) study designed to compare the performance of the PROMUS® Element™ Everolimus-Eluting Coronary Stent System to the XIENCE PRIME™ Everolimus-Eluting Coronary Stent System.

26 May 2010

Positive results reported from Phase IIa clinical trial of intranasal oxytocin for CDH

Trigemina, Inc., a Mountain View based privately-held biopharmaceutical company, reports positive results from a time-based interim analysis of its Phase IIa clinical trial in Chronic Daily Headache. The trial is a collaborative effort between Trigemina and Dr. Egilius Spierings of MedVadis Research Corporation located outside of Boston. The study compares intranasal oxytocin with placebo in patients suffering from CDH.

26 May 2010

NEVO Sirolimus-eluting Coronary Stent demonstrates safety and efficacy outcomes at 12 months

At 12 months the NEVO™ Sirolimus-eluting Coronary Stent has continued to demonstrate excellent safety and efficacy outcomes compared to Taxus® Liberte® according to new data presented today from the NEVO™ RES-I clinical trial. These results were presented as a late breaking trial at EuroPCR, the leading medical conference in Europe for physicians specializing in interventional cardiovascular medicine.

26 May 2010

HDL cholesterol can transform from good to bad actor in heart-disease process

We've all heard about the importance of raising HDL, or the so-called "good" cholesterol, and lowering LDL, or "bad" cholesterol, to improve heart health. While we've come to assume HDL cholesterol is an inherently good thing, a new study shows that for a certain group of patients, this is not always the case. The study is the first to find that a high level of the supposedly good cholesterol places a subgroup of patients at high risk for recurrent coronary events, such as chest pain, heart attack, and death.

26 May 2010

Osteopathic manipulative medicine reduces length of hospital stays for pneumonia patients: Research

Older patients battling pneumonia spent less time in the hospital when treated using osteopathic manipulative medicine - a drug-free form of hands-on medical care focusing on increasing muscle motion - in addition to conventional care, recently published research shows.

26 May 2010

GTx reports top line results from toremifene Phase III clinical trial for prostate cancer

GTx, Inc. today announced top line results of the Phase III clinical trial evaluating toremifene 20 mg, a selective estrogen receptor modulator, for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia, or PIN, a premalignant lesion of the prostate.

26 May 2010

Rockwell Medical's SFP Phase IIb data accepted for presentation at XLVII ERA-EDTA Congress

Rockwell Medical, a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency anemia, announced today that Phase IIb data for its lead drug candidate Soluble Ferric Pyrophosphate (SFP) have been accepted for presentation at the XLVII European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Congress, organized in collaboration with the Deutsche Gesellschaft fur Nephrologie (DGfN) in Munich, Germany, June 25-28, 2010.

25 May 2010

FDA grants priority review for Alkermes' VIVITROL sNDA for opioid dependence

Alkermes, Inc. today announced that the supplemental New Drug Application (sNDA) for VIVITROL® (naltrexone for extended-release injectable suspension) for opioid dependence has been designated a priority review by the U.S. Food and Drug Administration (FDA).

25 May 2010

DAPT Study expands into seven countries in the EU: HCRI

The Harvard Clinical Research Institute announced today that the DAPT Study has expanded into seven countries in the European Union. John Irving, MBChB, MRCP, M.D., consultant cardiologist at Ninewells Hospital in Dundee, United Kingdom, was the first European investigator to enroll patients into the study.

25 May 2010

Preclinical results of AMEP for metastatic melanoma presented at ASGCT Annual Meeting

BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, has presented efficacy, safety and biodistribution results on its new biotherapy AMEP™ for advanced and metastatic melanoma at the 13th Annual Meeting of the American Society of Gene and Cell Therapy in Washington, DC (May 17 - 22, 2010).

25 May 2010

Clinical Trial News and Research

Cordis announces launch of ExoSeal Vascular Closure Device

UCI scientists create eight-layer, early-stage retina from human embryonic stem cells

Modified measles virus may hold potential for treatment of medulloblastoma

Nottingham scientists given green light to test new vaccine for malignant melanoma

PBI awarded contract to provide essential laboratory data for Phase I cardiovascular trial

Cardiovascular Systems initiates enrollment in ORBIT II IDE clinical trial of Diamondback 360 System

CTRC starts enrolment in Phase 2 combination trial of REOLYSIN and gemcitabine for advanced pancreatic cancer

New clinical data for CoreValve transcatheter aortic valve replacement system presented at EuroPCR

Medtronic’s Resolute zotarolimus-eluting stent as effective as Xience V everolimus-eluting stent: Study

6-month results of NovoStent's SAMBA trial for atherosclerotic disease in SFA and popliteal arteries

Boston Scientific initiates study to compare PROMUS Element Stent to XIENCE PRIME Stent System

Positive results reported from Phase IIa clinical trial of intranasal oxytocin for CDH

NEVO Sirolimus-eluting Coronary Stent demonstrates safety and efficacy outcomes at 12 months

HDL cholesterol can transform from good to bad actor in heart-disease process

Osteopathic manipulative medicine reduces length of hospital stays for pneumonia patients: Research

GTx reports top line results from toremifene Phase III clinical trial for prostate cancer

Rockwell Medical's SFP Phase IIb data accepted for presentation at XLVII ERA-EDTA Congress

FDA grants priority review for Alkermes' VIVITROL sNDA for opioid dependence

DAPT Study expands into seven countries in the EU: HCRI

Preclinical results of AMEP for metastatic melanoma presented at ASGCT Annual Meeting

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer